Functional Concept
FDA Grants Approval to ImmunityBio’s Innovative Combination Therapy for Bladder Cancer
FDA, ImmunityBio, bladder cancer, combination therapy, approval, innovative treatment, immunotherapy, clinical trials
ImmunityBio’s Innovative IL-15 Superagonist Receives FDA Approval for Non-Muscle Invasive Bladder Cancer Treatment
ImmunityBio, FDA Approval, IL-15 Superagonist, Non-Muscle Invasive Bladder Cancer (NMIBC), Immunotherapy, Cancer Treatment
Ipsen and Skyhawk Therapeutics Join Forces in a $1.8 Billion Deal to Advance RNA Modulator Research
Ipsen, Skyhawk Therapeutics, RNA modulators, drug discovery, partnership, $1.8 billion, biopharmaceutical, R&D, therapeutic development
Roche’s Alecensa Gains FDA Approval for Postsurgical Early Lung Cancer Treatment
Roche, Alecensa, FDA approval, Postsurgical treatment, Early lung cancer
Sanofi Restructures US Commercial Vaccine Group Amid Cost-Saving Campaign
Sanofi, Restructuring, US Commercial Vaccine Group, Cost-Savings Campaign, Streamlined Strategic Sales Structure, Evolving Vaccine Market, Optimization for Efficiency and Effectiveness, Employee Support and Outplacement Assistance
Alecensa: FDA-Approved First ALK Inhibitor for Adjuvant Treatment in Early-Stage ALK-Positive NSCLC
Alecensa, ALK Inhibitor, Adjuvant Treatment, Early-Stage ALK-Positive NSCLC, FDA Approval, Genentech, Roche Group, ALINA Study, 76% Reduction in Disease Recurrence or Death, NCCN Guidelines
Metsera Emerges with $290M to Rival Obesity Pharmaceutical Giants Lilly and Novo
Metsera, $290M funding, Obesity treatment, Challenge Lilly and Novo, GLP-1 receptor agonist (Phase I injectable)
MedinCell and AbbVie Collaborate on Long-Acting Injectable Development with a Potential Value of $1.9 Billion
MedinCell, AbbVie, Long-acting injectable, Development pact, $1.9 billion
Director/Vice President of Translational Research: Leading the Bridge from Discovery to Clinical Development
Translational Research, Biomarker Discovery, Preclinical Development, Early Clinical Development, Drug Molecule Development, Translational Science Leadership, Biomarker Development, Target Engagement Strategies, Assay Development (PK/ PD/ Immunogenicity), Clinical Trial Design, Endpoint and Biomarker Strategy, Team Building and Leadership, Cross-Functional Collaboration, Regulatory Approvals
Detailed PHOENIX Study Reveals Relyvrio’s Failure in ALS Treatment
Relyvrio, PHOENIX study, Amyotrophic Lateral Sclerosis (ALS), Trial failure, Amylyx Pharmaceuticals